Estrella Immunopharma Reports 100% Complete Response Rate in STARLIGHT-1 EB103 Trial Cohort

Reuters

11/07

<a href="https://laohu8.com/S/ESLA">Estrella Immunopharma</a> Reports 100% Complete Response Rate in STARLIGHT-1 EB103 Trial Cohort

Estrella Immunopharma Inc. announced the successful completion of the second dose cohort in the Phase I portion of its STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy for patients with advanced B-cell Non-Hodgkin's Lymphomas (NHL). According to the company, all evaluable patients in this high-risk group-including those not suitable for commercial CD19 products and one with central nervous system involvement-achieved a 100% complete response rate at Month 1. No treatment-related serious adverse events were reported in this cohort. The results have been announced by the company, and a Data and Safety Monitoring Board will review the cumulative study data to determine the recommended Phase II dose for the trial's expansion phase. Further details are available under clinical trial identifier NCT06343311.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-107249), on November 06, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2581049819"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581049819\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581049819?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 06:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581049819","market":"us","top_or_hot":-1,"title":"Estrella Immunopharma Reports 100% Complete Response Rate in STARLIGHT-1 EB103 Trial Cohort","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ESLA\">Estrella Immunopharma</a> Reports 100% Complete Response Rate in STARLIGHT-1 EB103 Trial Cohort\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ESLAW\">Estrella Immunopharma Inc.</a> announced the successful completion of the second dose cohort in the Phase I portion of its STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy for patients with advanced B-cell Non-Hodgkin's Lymphomas (NHL). According to the company, all evaluable patients in this high-risk group-including those not suitable for commercial CD19 products and one with central nervous system involvement-achieved a 100% complete response rate at Month 1. No treatment-related serious adverse events were reported in this cohort. The results have been announced by the company, and a Data and Safety Monitoring Board will review the cumulative study data to determine the recommended Phase II dose for the trial's expansion phase. Further details are available under clinical trial identifier NCT06343311.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-107249), on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Estrella Immunopharma Reports 100% Complete Response Rate in STARLIGHT-1 EB103 Trial Cohort</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEstrella Immunopharma Reports 100% Complete Response Rate in STARLIGHT-1 EB103 Trial Cohort\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-07 06:18</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ESLA\">Estrella Immunopharma</a> Reports 100% Complete Response Rate in STARLIGHT-1 EB103 Trial Cohort\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ESLAW\">Estrella Immunopharma Inc.</a> announced the successful completion of the second dose cohort in the Phase I portion of its STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy for patients with advanced B-cell Non-Hodgkin's Lymphomas (NHL). According to the company, all evaluable patients in this high-risk group-including those not suitable for commercial CD19 products and one with central nervous system involvement-achieved a 100% complete response rate at Month 1. No treatment-related serious adverse events were reported in this cohort. The results have been announced by the company, and a Data and Safety Monitoring Board will review the cumulative study data to determine the recommended Phase II dose for the trial's expansion phase. Further details are available under clinical trial identifier NCT06343311.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-107249), on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ESLA","symbol_name":"Estrella Immunopharma","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL6zNthp:1","article_id":"2581049819","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581049819","pubTimestamp":1762467480,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Estrella Immunopharma Inc. announced the successful completion of the second dose cohort in the Phase I portion of its STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-redirected ARTEMIS T-cell therapy for patients with advanced B-cell Non-Hodgkin's Lymphomas . According to the company, all evaluable patients in this high-risk group-including those not suitable for commercial CD19 products and one with central nervous system involvement-achieved a 100% complete response rate at Month 1. No treatment-related serious adverse events were reported in this cohort. The results have been announced by the company, and a Data and Safety Monitoring Board will review the cumulative study data to determine the recommended Phase II dose for the trial's expansion phase. Further details are available under clinical trial identifier NCT06343311.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ESLA":"Estrella Immunopharma","BK4139":"生物科技"},"translate_title":"Estrella Immunopharma报告STARLIGHT-1 EB103试验队列100%完全缓解率","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ESLA":0.9},"content_text":"Estrella Immunopharma Reports 100% Complete Response Rate in STARLIGHT-1 EB103 Trial Cohort\n    \n\nEstrella Immunopharma Inc. announced the successful completion of the second dose cohort in the Phase I portion of its STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy for patients with advanced B-cell Non-Hodgkin's Lymphomas (NHL). According to the company, all evaluable patients in this high-risk group-including those not suitable for commercial CD19 products and one with central nervous system involvement-achieved a 100% complete response rate at Month 1. No treatment-related serious adverse events were reported in this cohort. The results have been announced by the company, and a Data and Safety Monitoring Board will review the cumulative study data to determine the recommended Phase II dose for the trial's expansion phase. Further details are available under clinical trial identifier NCT06343311.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-107249), on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}